AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteTG 100713 is an inhibitor of PI3-kinase that inhibits endothelial cell proliferation.
More Information Supplier PageTG 100713 is an inhibitor of PI3-kinase that inhibits endothelial cell proliferation.
More Information Supplier PageTG 100713 is an inhibitor of PI3-kinase that inhibits endothelial cell proliferation.
More Information Supplier PageTG 100713 is an inhibitor of PI3-kinase that inhibits endothelial cell proliferation.
More Information Supplier PageTG 100801 is a VEGFR2 targeting prodrug currently in a clinical trial. The active form is TG100572.
More Information Supplier PageTG 100801 is a VEGFR2 targeting prodrug currently in a clinical trial. The active form is TG100572.
More Information Supplier PageTG 100801 is a VEGFR2 targeting prodrug currently in a clinical trial. The active form is TG100572.
More Information Supplier PageTG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
More Information Supplier PageTG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
More Information Supplier PageTG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
More Information Supplier PageTG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.
More Information Supplier PageTG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.
More Information Supplier PageTG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.
More Information Supplier PageTG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.
More Information Supplier PageTG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.
More Information Supplier PageTG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
More Information Supplier PageTG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
More Information Supplier PageTG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
More Information Supplier PageTG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
More Information Supplier PageTG100-115 inhibits PI3K ?? and -??(IC50 values of 83 and 235 nM, respectively).
More Information Supplier PageTG100-115 inhibits PI3K ?? and -??(IC50 values of 83 and 235 nM, respectively).
More Information Supplier PageTG100-115 inhibits PI3K ?? and -??(IC50 values of 83 and 235 nM, respectively).
More Information Supplier PageTG100-115 inhibits PI3K ?? and -??(IC50 values of 83 and 235 nM, respectively).
More Information Supplier PageTG100-115 inhibits PI3K ?? and -??(IC50 values of 83 and 235 nM, respectively).
More Information Supplier PageTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
More Information Supplier PageTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
More Information Supplier PageTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
More Information Supplier PageTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
More Information Supplier PageTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
More Information Supplier PageTGR5 Receptor Agonist is a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).
More Information Supplier PageTGR5 Receptor Agonist is a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).
More Information Supplier PageTGR5 Receptor Agonist is a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).
More Information Supplier PageTGR5 Receptor Agonist is a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).
More Information Supplier PageTGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110??.
More Information Supplier PageTGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110??.
More Information Supplier PageTGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110??.
More Information Supplier PageTGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110??.
More Information Supplier PageTGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110??.
More Information Supplier PageTH-237A is a novel neuroprotective agent, which possess protective properties against ??-amyloid (A??)-induced neurodegeneration associated with Alzheimer’s disease.
More Information Supplier PageTH-237A is a novel neuroprotective agent, which possess protective properties against ??-amyloid (A??)-induced neurodegeneration associated with Alzheimer’s disease.
More Information Supplier PageTH-237A is a novel neuroprotective agent, which possess protective properties against ??-amyloid (A??)-induced neurodegeneration associated with Alzheimer’s disease.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier Page
